EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC Dream Vector) therapy in patients with ...

Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.

FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with ...

The FDA has accepted a new drug application (NDA) for zipalertinib for the treatment of patients with locally advanced or ...

Of particular interest were novel therapies for EGFR exon 20 insertion mutations in non-small cell lung cancer, which ...

Janux Therapeutics Inc. JANX said it will discontinue development of its EGFR-targeted JANX008 program after internal ...

Patients with chronic kidney disease are often taken off RAS inhibitors after declines in kidney function, but the risks may ...

In this episode of The OncoloGIST, Dr Christine Bestvina of UChicago Medicine provides a comprehensive look at the rapidly ...

Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...